Acorda Therapeutics Will Regain Global Commercialization Rights To Fampyra (Fampridine) Following A Decision By Biogen To Terminate The License And Collaboration Agreement, Effective January 1, 2025
Portfolio Pulse from Benzinga Newsdesk
Acorda Therapeutics will regain the global commercialization rights to Fampyra, a medication for improving walking in adults with MS, after Biogen decided to terminate their license and collaboration agreement, effective January 1, 2025. Acorda markets Fampyra as AMPYRA in the U.S.
January 11, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's termination of the Fampyra agreement with Acorda may indicate a strategic shift or a focus on other products in its pipeline.
The termination of the Fampyra agreement by Biogen could reflect a strategic realignment or a decision to concentrate on other areas. The short-term impact on the stock is uncertain without details on the reasons for the termination or potential financial implications.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Acorda Therapeutics regaining global rights to Fampyra could lead to increased revenue potential and greater control over the drug's commercial strategy.
Acorda regaining rights to Fampyra suggests a potential increase in revenue and market presence. However, the impact may be moderated by the time until the agreement's termination in 2025 and the company's ability to leverage these rights effectively.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80